202 related articles for article (PubMed ID: 15936846)
41. Transcriptional expression of survivin and its splice variants in cervical carcinomas.
Futakuchi H; Ueda M; Kanda K; Fujino K; Yamaguchi H; Noda S
Int J Gynecol Cancer; 2007; 17(5):1092-8. PubMed ID: 17877643
[TBL] [Abstract][Full Text] [Related]
42. Gene expression profiling revealed survivin as a target of 3,3'-diindolylmethane-induced cell growth inhibition and apoptosis in breast cancer cells.
Rahman KW; Li Y; Wang Z; Sarkar SH; Sarkar FH
Cancer Res; 2006 May; 66(9):4952-60. PubMed ID: 16651453
[TBL] [Abstract][Full Text] [Related]
43. Adenovirus-mediated transfer of siRNA against survivin enhances the radiosensitivity of human non-small cell lung cancer cells.
Yang CT; Li JM; Weng HH; Li YC; Chen HC; Chen MF
Cancer Gene Ther; 2010 Feb; 17(2):120-30. PubMed ID: 19730451
[TBL] [Abstract][Full Text] [Related]
44. Do the survivin (BIRC5) splice variants modulate or add to the prognostic value of total survivin in breast cancer?
Span PN; Tjan-Heijnen VC; Heuvel JJ; de Kok JB; Foekens JA; Sweep FC
Clin Chem; 2006 Sep; 52(9):1693-700. PubMed ID: 16873289
[TBL] [Abstract][Full Text] [Related]
45. [Expression of survivin and its clinical significance in non-small cell lung cancer].
Ren YJ; Zhang QY
Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Oct; 37(5):504-7. PubMed ID: 16224523
[TBL] [Abstract][Full Text] [Related]
46. MicroRNA-mediated epigenetic targeting of Survivin significantly enhances the antitumor activity of paclitaxel against non-small cell lung cancer.
Wang S; Zhu L; Zuo W; Zeng Z; Huang L; Lin F; Lin R; Wang J; Lu J; Wang Q; Lin L; Dong H; Wu W; Zheng K; Cai J; Yang S; Ma Y; Ye S; Liu W; Yu Y; Tan J; Liu B
Oncotarget; 2016 Jun; 7(25):37693-37713. PubMed ID: 27177222
[TBL] [Abstract][Full Text] [Related]
47. A new tumor suppressor DnaJ-like heat shock protein, HLJ1, and survival of patients with non-small-cell lung carcinoma.
Tsai MF; Wang CC; Chang GC; Chen CY; Chen HY; Cheng CL; Yang YP; Wu CY; Shih FY; Liu CC; Lin HP; Jou YS; Lin SC; Lin CW; Chen WJ; Chan WK; Chen JJ; Yang PC
J Natl Cancer Inst; 2006 Jun; 98(12):825-38. PubMed ID: 16788156
[TBL] [Abstract][Full Text] [Related]
48. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY
Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429
[TBL] [Abstract][Full Text] [Related]
49. Forced expression of survivin-2B abrogates mitotic cells and induces mitochondria-dependent apoptosis by blockade of tubulin polymerization and modulation of Bcl-2, Bax, and survivin.
Ling X; Cheng Q; Black JD; Li F
J Biol Chem; 2007 Sep; 282(37):27204-27214. PubMed ID: 17656368
[TBL] [Abstract][Full Text] [Related]
50. Prognostic significance and different properties of survivin splicing variants in gastric cancer.
Meng H; Lu C; Mabuchi H; Tanigawa N
Cancer Lett; 2004 Dec; 216(2):147-55. PubMed ID: 15533590
[TBL] [Abstract][Full Text] [Related]
51. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
[TBL] [Abstract][Full Text] [Related]
52. Cell growth inhibition and down-regulation of survivin by silibinin in a laryngeal squamous cell carcinoma cell line.
Bang CI; Paik SY; Sun DI; Joo YH; Kim MS
Ann Otol Rhinol Laryngol; 2008 Oct; 117(10):781-5. PubMed ID: 18998509
[TBL] [Abstract][Full Text] [Related]
53. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib.
Morgillo F; Kim WY; Kim ES; Ciardiello F; Hong WK; Lee HY
Clin Cancer Res; 2007 May; 13(9):2795-803. PubMed ID: 17473213
[TBL] [Abstract][Full Text] [Related]
54. The role of survivin on overall survival of non-small cell lung cancer, a meta-analysis of published literatures.
Fan J; Wang L; Jiang GN; He WX; Ding JA
Lung Cancer; 2008 Jul; 61(1):91-6. PubMed ID: 18192073
[TBL] [Abstract][Full Text] [Related]
55. Survivin-deltaEx3: a novel biomarker for diagnosis of papillary thyroid carcinoma.
Vandghanooni S; Eskandani M; Montazeri V; Halimi M; Babaei E; Feizi MA
J Cancer Res Ther; 2011; 7(3):325-30. PubMed ID: 22044815
[TBL] [Abstract][Full Text] [Related]
56. Induction of death receptor 5 and suppression of survivin contribute to sensitization of TRAIL-induced cytotoxicity by quercetin in non-small cell lung cancer cells.
Chen W; Wang X; Zhuang J; Zhang L; Lin Y
Carcinogenesis; 2007 Oct; 28(10):2114-21. PubMed ID: 17548900
[TBL] [Abstract][Full Text] [Related]
57. Apoptosis gene signature of Survivin and its splice variant expression in breast carcinoma.
Végran F; Boidot R; Bonnetain F; Cadouot M; Chevrier S; Lizard-Nacol S
Endocr Relat Cancer; 2011 Dec; 18(6):783-92. PubMed ID: 21878572
[TBL] [Abstract][Full Text] [Related]
58. Expression level of wild-type survivin in gastric cancer is an independent predictor of survival.
Meng H; Lu CD; Sun YL; Dai DJ; Lee SW; Tanigawa N
World J Gastroenterol; 2004 Nov; 10(22):3245-50. PubMed ID: 15484293
[TBL] [Abstract][Full Text] [Related]
59. In vivo expression of survivin and its splice variant survivin-2B: impact on clinical outcome in acute myeloid leukemia.
Wagner M; Schmelz K; Wuchter C; Ludwig WD; Dörken B; Tamm I
Int J Cancer; 2006 Sep; 119(6):1291-7. PubMed ID: 16619249
[TBL] [Abstract][Full Text] [Related]
60. Elevated expression of survivin-splice variants predicts a poor outcome for soft-tissue sarcomas patients.
Taubert H; Kappler M; Bache M; Bartel F; Köhler T; Lautenschläger C; Blümke K; Würl P; Schmidt H; Meye A; Hauptmann S
Oncogene; 2005 Aug; 24(33):5258-61. PubMed ID: 15856009
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
